C4 Therapeutics, Inc. Other Operating Activities, Cash Flow Statement
C4 Therapeutics, Inc. (CCCC) reported Other Operating Activities, Cash Flow Statement of $42.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherOperatingActivitiesCashFlowStatement · last filed 2026-08-11
- C4 Therapeutics, Inc. other operating activities, cash flow statement for the quarter ending 2026-06-30 was $12.00K, a 45.45% decline year-over-year.
- C4 Therapeutics, Inc. other operating activities, cash flow statement for the quarter ending 2026-03-31 was $30.00K, a 15.38% increase year-over-year.
- C4 Therapeutics, Inc. other operating activities, cash flow statement for the quarter ending 2025-12-31 was $21.00K.
- C4 Therapeutics, Inc. other operating activities, cash flow statement for the quarter ending 2025-09-30 was $30.00K, a 3.23% decline year-over-year.
- C4 Therapeutics, Inc. other operating activities, cash flow statement for fiscal 2025 was $99.00K, a 1550.00% increase from fiscal 2024.
- C4 Therapeutics, Inc. other operating activities, cash flow statement for fiscal 2024 was $6.00K, a 92.21% decline from fiscal 2023.
- C4 Therapeutics, Inc. other operating activities, cash flow statement for fiscal 2023 was $77.00K.
- C4 Therapeutics, Inc. other operating activities, cash flow statement for fiscal 2022 was $0.00.
| Period end | Other Operating Activities, Cash Flow Statement 3 month | Other Operating Activities, Cash Flow Statement 6 month | Other Operating Activities, Cash Flow Statement 9 month | Other Operating Activities, Cash Flow Statement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $42.00K 10-Q · filed 2026-08-11 | $63.00K derived: sum of 3 quarters · filed 2026-08-11 | $93.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $30.00K 10-Q · filed 2026-05-12 | $51.00K derived: sum of 2 quarters · filed 2026-05-12 | $81.00K derived: sum of 3 quarters · filed 2026-05-12 | $103.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $51.00K derived: sum of 2 quarters · filed 2026-02-26 | $73.00K derived: sum of 3 quarters · filed 2026-08-11 | $99.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $52.00K derived: sum of 2 quarters · filed 2026-08-11 | $78.00K 10-Q · filed 2025-11-06 | $31.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $48.00K 10-Q · filed 2026-08-11 | $1.00K derived: sum of 3 quarters · filed 2026-08-11 | $32.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $26.00K 10-Q · filed 2026-05-12 | -$21.00K derived: sum of 2 quarters · filed 2026-05-12 | $10.00K derived: sum of 3 quarters · filed 2026-05-12 | $123.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$16.00K derived: sum of 2 quarters · filed 2026-02-26 | $97.00K derived: sum of 3 quarters · filed 2026-02-26 | $6.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $144.00K derived: sum of 2 quarters · filed 2025-11-06 | $53.00K 10-Q · filed 2025-11-06 | $10.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $22.00K 10-Q · filed 2025-08-07 | -$21.00K derived: sum of 3 quarters · filed 2025-08-07 | $31.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$91.00K 10-Q · filed 2025-05-07 | -$134.00K derived: sum of 2 quarters · filed 2025-05-07 | -$82.00K derived: sum of 3 quarters · filed 2025-05-07 | -$46.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $9.00K derived: sum of 2 quarters · filed 2025-02-27 | $45.00K derived: sum of 3 quarters · filed 2025-02-27 | $77.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $88.00K derived: sum of 2 quarters · filed 2024-10-31 | $120.00K 10-Q · filed 2024-10-31 | $120.00K derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $68.00K 10-Q · filed 2024-08-01 | $68.00K derived: sum of 3 quarters · filed 2024-08-01 | $68.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $32.00K 10-Q · filed 2024-05-08 | $32.00K derived: sum of 2 quarters · filed 2024-05-08 | $32.00K derived: sum of 3 quarters · filed 2024-05-08 | $32.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |